Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Dynamic Pharmaceuticals Powershares (PJP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [AMEX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [AMEX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart
Realtime quote and/or trade prices are not sourced from all markets.

Fund basics

See More
  • Fund Family Invesco PowerShares
  • Assets Under Management 733,431,100
  • Shares Outstanding, K 10,950

Price Performance

See More
Period Period Low Period High Performance
1-Month
60.86 +2.14%
on 11/15/17
66.35 -6.31%
on 10/20/17
-3.74 (-5.68%)
since 10/17/17
3-Month
59.74 +4.05%
on 08/18/17
67.35 -7.71%
on 10/06/17
+1.83 (+3.03%)
since 08/17/17
52-Week
53.56 +16.06%
on 12/07/16
67.35 -7.71%
on 10/06/17
+3.37 (+5.73%)
since 11/17/16

Most Recent Stories

More News
Pharma ETFs Down Post Q3 Earnings

The string of earnings beat failed to boost pharma ETFs as they saw rough trading over the past one month.

XPH : 41.90 (+0.19%)
JNJ : 138.00 (-0.63%)
MRK : 55.20 (+0.05%)
PJP : 62.16 (unch)
IHE : 150.60 (-0.38%)
LLY : 82.89 (-0.66%)
PPH : 56.00 (+0.23%)
PFE : 35.37 (-0.53%)
BMY : 61.32 (-0.89%)
Pharma ETFs Down Post Q3 Earnings

The string of earnings beat failed to boost pharma ETFs as they saw rough trading over the past one month.

XPH : 41.90 (+0.19%)
JNJ : 138.00 (-0.63%)
MRK : 55.20 (+0.05%)
PJP : 62.16 (unch)
IHE : 150.60 (-0.38%)
LLY : 82.89 (-0.66%)
PPH : 56.00 (+0.23%)
PFE : 35.37 (-0.53%)
BMY : 61.32 (-0.89%)
What Lies in Store for Pharma ETFs?

Pharma stocks have done well this year; what lies ahead?

XPH : 41.90 (+0.19%)
PJP : 62.16 (unch)
IHE : 150.60 (-0.38%)
PPH : 56.00 (+0.23%)
What Lies in Store for Pharma ETFs?

Pharma stocks have done well this year; what lies ahead?

XPH : 41.90 (+0.19%)
PJP : 62.16 (unch)
IHE : 150.60 (-0.38%)
PPH : 56.00 (+0.23%)
Q2 Earnings Fail to Impress Pharma ETF

The string of earnings beat failed to boost pharma ETFs.

XPH : 41.90 (+0.19%)
JNJ : 138.00 (-0.63%)
MRK : 55.20 (+0.05%)
IHE : 150.60 (-0.38%)
PJP : 62.16 (unch)
LLY : 82.89 (-0.66%)
PFE : 35.37 (-0.53%)
BMY : 61.32 (-0.89%)
Q2 Earnings Fail to Impress Pharma ETF

The string of earnings beat failed to boost pharma ETFs.

XPH : 41.90 (+0.19%)
JNJ : 138.00 (-0.63%)
MRK : 55.20 (+0.05%)
IHE : 150.60 (-0.38%)
PJP : 62.16 (unch)
LLY : 82.89 (-0.66%)
PFE : 35.37 (-0.53%)
BMY : 61.32 (-0.89%)
What Lies Ahead for Pharma ETFs in Second Half 2017

We discuss some of the factors that could contribute to a sustained recovery in the sector.

XPH : 41.90 (+0.19%)
PJP : 62.16 (unch)
IHE : 150.60 (-0.38%)
PPH : 56.00 (+0.23%)
What Lies Ahead for Pharma ETFs in Second Half 2017

We discuss some of the factors that could contribute to a sustained recovery in the sector.

XPH : 41.90 (+0.19%)
PJP : 62.16 (unch)
IHE : 150.60 (-0.38%)
PPH : 56.00 (+0.23%)
Gilead Sciences Posts Mixed Q1 Results: ETFs in Focus

Gilead beat Zacks EPS estimates, but missed on revenue, in the first quarter of 2017.

PJP : 62.16 (unch)
IBB : 311.21 (+0.13%)
BBH : 124.34 (+0.26%)
GILD : 72.44 (+0.04%)
Gilead Sciences Posts Mixed Q1 Results: ETFs in Focus

Gilead beat Zacks EPS estimates, but missed on revenue, in the first quarter of 2017.

PJP : 62.16 (unch)
IBB : 311.21 (+0.13%)
BBH : 124.34 (+0.26%)
GILD : 72.44 (+0.04%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators mostly agree with the trend.

See More

Fund Summary

The PowerShares Dynamic Pharmaceuticals Portfolio is based on the Dynamic Pharmaceutical Intellidex Index. The Fund will normally invest at least 90% of its total assets in common stocks that comprise the Index. The Intellidex Index is designed to provide capital appreciation by thoroughly evaluating...

See More

Top 10 Holdings

Key Turning Points

2nd Resistance Point 62.64
1st Resistance Point 62.40
Last Price 62.16
1st Support Level 61.75
2nd Support Level 61.34

See More

52-Week High 67.35
Last Price 62.16
Fibonacci 61.8% 62.08
Fibonacci 50% 60.46
Fibonacci 38.2% 58.83
52-Week Low 53.56

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart